We analyzed the incidence and risk factors for ocular GVHD in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) in Korea. In this retrospective, noncomparative, observational study, 635 subjects were included who had at least 2 years of follow-up ophthalmological examinations after allo-HSCT from 2009 to 2012 at Seoul St Mary's Hospital, Seoul, Korea. The mean duration between allo-HSCT and onset of ocular GVHD was 225.5 ± 194.3 days. The adjusted incidence for acute ocular GVHD was 1.33% and that for chronic GVHD was 33.33%. In the multivariate analysis, preexisting diabetes mellitus (odds ratio (OR): 4.22, 95% confidence interval (CI): 1.66-10.72), repeated allo-HSCT (OR: 29.10, 95% CI: 1.02-8.28) and the number of organs that chronically developed GVHD by stage I (OR: 14.63, 95% CI: 9.81-21.84) increased risk of ocular GVHD. Careful monitoring of ocular GVHD is needed in patients with chronic GVHD in multiple organs and preexisting diabetes.
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) from HLA-matched related or unrelated donors is used as a curative therapy for malignant and nonmalignant hematological diseases.
1,2 However, chronic GVHD remains the major reason for non-relapse morbidity and mortality in patients undergoing allo-HSCT. The manifestations of chronic GVHD may be restricted to a single organ or tissue or may be widespread. 3, 4 Ocular manifestations of GVHD are known to occur in 60-90% of patients with chronic GVHD, and these manifestations primarily affect the cornea, conjunctiva, lacrimal glands, eyelid and meibomian glands. 5, 6 Dry eye disease (DED), or keratoconjunctivitis sicca (KCS), is the most common manifestation of ocular GVHD and induces ocular discomfort, decreases patients' quality of life and can even result in loss of vision. 7, 8 The National Institutes of Health (NIH) has defined the distinctive manifestations of ocular GVHD as new ocular sicca documented by low Schirmer test values (mean for both eyes of ⩽ 5 mm at 5 min) or a new onset of KCS by slit lamp examination (mean Schirmer values of 6-10 mm). If accompanied by distinctive manifestations in at least one other organ, these conditions are sufficient for a diagnosis of chronic GVHD. 9 The incidence of ocular GVHD in transplant survivors varies, and the risk factors are not well understood owing to discrepancies in the results of various studies. [10] [11] [12] [13] Similarly, the diagnosis of DED is complicated by the lack of objective tests with sufficient and specific clinical tools.
14 Although the Schirmer test remains the main test used by ophthalmologists to diagnose DED, it is unreliable, and its results are difficult to replicate in the clinical setting. Moreover, ocular GVHD is often overlooked or misdiagnosed by physicians when patients complain of ocular discomfort. 15 Given the importance of a diagnosis of ocular GVHD in confirming chronic GVHD, information must be gathered from ophthalmologists and hematological oncology specialists regarding the incidence and risk factors for ocular GVHD. Therefore, we conducted this study to elucidate the overall incidence and risk factors for ocular GVHD in Korea. An increased understanding of risk factors would also help to identify candidates for early treatment aimed at reducing the visual threat related to ocular GVHD after allo-HSCT.
MATERIALS AND METHODS Patients
This retrospective, noncomparative, observational study was approved by the Seoul St Mary's Hospital Institutional Review Board. We identified 747 patients who were newly diagnosed with hematological diseases and underwent allo-HSCT between January 2009 and December 2012 at the Department of Hematology, Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, Korea. Patients were excluded if they had no clinical history at the Department of Ophthalmology or did not survive at least 12 weeks after the allo-HSCT. We created a final cohort of 635 patients who had a follow-up ophthalmological examination on day 100 and ⩾ 1 years after the allo-HSCT; these patients were all included in this analysis. A high number of patients were excluded from our study, because they did not complete two visits to our ophthalmology department; therefore, we compared the demographic characteristics of the study patients and the excluded patients during the study period, which showed that there were no significant differences between the two groups in terms of age, gender or causative hematological diseases ( Table 1) . The treatment policy at our institution is as follows: allo-HSCT is offered according to donor availability and the presence of high-risk features, as previously described. 16 If an 8/8-matched related donor is available, the related donor HSCT is offered to any patient, regardless of risk assessment, after completion of the first consolidation course. If a suitably matched unrelated donor (⩽ 2 mismatched alleles) is available, the unrelated donor HSCT is offered to high-risk patients as early as possible, typically depending on the speed of the coordination process.
All study patients received GVHD prophylaxis, management and supportive care for GVHD. A combination of tacrolimus (continuous IV infusion with a starting dose of 0.03 mg/kg from days − 1 to +21 and then per os (p.o.) postoperatively at a total of 0.12 mg kg − 1 day
) and shortcourse methotrexate (10 mg/m 2 IV bolus injection on days +1, +3, +6 and +11) was used for GVHD prophylaxis in all patients, as described previously. 17 The dosage of tacrolimus was adjusted for each patient based on the plasma level to maintain a target dose of 8-12 ng/mL. The administration of tacrolimus was gradually reduced from day +90 after transplantation when there was no evidence of acute GVHD. The treatment of chronic GVHD also varied but according to the NIH criteria; 9 the mild type was treated with a topical immunosuppressant, while moderate and severe types were treated with a calcineurin inhibitor along with systemic steroids.
Clinical assessments and definitions
Patient records were reviewed for ocular and non-ocular GVHD after allo-HSCT until the last follow-up, relapse or death. Diagnosis of ocular GVHD at 100 days was based on the NIH definition (a low Schirmer test value (⩽5 mm at 5 min) or new KSC with moderate Schirmer test value (6-10 mm at 5 min)) by cornea and external eye specialists. 9 Because not all patients underwent a baseline ophthalmic examination, new onset was documented by using the patient's information. Periodic examinations 3-6 months after the initial visit were performed in the Department of Ophthalmology. Grading of ocular GVHD was based on the NIH consensus criteria. 9, 10 Subjective symptoms, best corrected visual acuity, slit lamp examination, intraocular pressure, Schirmer test results, tear break-up time and fluorescein corneal staining were also examined. Anterior segment photographs were obtained to classify the severity of ocular GVHD ( Figure 1 ). GVHD in other organs (except the eye) was diagnosed by hematology oncology specialists. Only patients with preexisting diabetes before HSCT were considered to have diabetes, because steroid administration for the treatment of GVHD is likely to cause diabetes and, therefore, may result in confounding findings.
Statistical analysis
Statistical analysis was performed using the SAS software (version 9.3, SAS institute, Cary, NC, USA). Descriptive statistics were calculated, including the mean and SD for continuous variables and frequencies and percentage for categorical variables. Groups with continuous outcomes were compared using a T-test and groups with categorical outcomes were compared using the chi-square test. The changes of GVHD grading between the initial visit and 2 years after the visit were analyzed using McNemar's test to compare paired nominal data, and the linear trend of GVHD according to the number of acutely and chronically involved organs was tested using the Mantel-Haenszel chi-square. To define the risk factors that affected ocular GVHD occurrence, multivariable analysis was performed using stepwise logistic regression analysis. A P-value of o0.05 was considered statistically significant. Table 1 . The causative hematological diseases were AML (n = 247, 38.90%), ALL (n = 133, 20.94%), myelodysplastic syndrome (n = 113, 17.80%), CML (n = 12, 1.89%), severe aplastic anemia (n = 87, 13.70%), multiple myeloma (n = 14, 2.20%) and others. The mean duration between allo-HSCT and the onset of ocular GVHD was 225.5 ± 194.3 days. The incidence of acute ocular GVHD was lower (n = 10, 1.57%) than that of chronic ocular GVHD (n = 249, 39.21%). Because a total of 747 patients underwent allo-HSCT during the study period, the adjusted incidence was 1.33% for acute ocular GVHD and 33.33% for chronic ocular GVHD.
RESULTS

Patient demographics are listed in
We classified the subjects according to the onset of ocular GVHD and compared the prevalence of systemic GVHD in the ocular and non-ocular GVHD groups. In the ocular GVHD group (n = 249), the subjects exhibited acute systemic GVHD (n = 182, 73.09%) and chronic systemic GVHD (n = 67, 26.91%) in the nonocular organs, although none showed exclusively ocular GVHD. In the non-ocular GVHD group (n = 386), the subjects exhibited acute systemic GVHD (n = 159, 41.19%) and chronic systemic GVHD (n = 47, 12.18%) in the non-ocular organs; no systemic GVHD was also observed (n = 80, 12.60%).
The severity of ocular GVHD was graded according to the NIH consensus criteria, and the grading was re-evaluated 2 years after the onset of GVHD. There was no difference in the severity of ocular GVHD when the initial ocular GVHD diagnosis and 2-year follow-up visit were compared (P = 0.139, Table 2 ). At the onset of ocular GVHD, 202 patients (81.12%) were grade I, 32 patients (12.85%) were grade II and 15 patients (6.02%) were grade III. After 2 years, the ocular GVHD had resolved in 2 patients (0.80%), 203 patients (81.53%) were grade I, 37 patients (14.86%) were grade II, 4 patients (1.61%) were grade III and 2 patients (0.80%) were grade IV.
In the univariate analysis, acute GVHD in non-ocular organs (P o 0.001), a hematological diagnosis (P o0.001), classification of allo-HSCT (P = 0.0014), use of antithymocyte globulin as a prophylactic regimen (P = 0.0002), the number of acutely involved organs (P o 0.0001), and the number of chronically involved organs (P o 0.0001) were statistically different between the ocular and non-ocular GVHD groups ( (Table 4) . Among these risk factors, the likelihood of ocular GVHD increased with increasing numbers of chronically involved organs in a trend analysis (P for trend o 0.001). However, the number of acutely involved organs was not related to the onset of ocular GVHD (data not shown).
The incidence of acute GVHD in the skin, gastrointestinal tract and liver was significantly higher in the ocular GVHD group compared with the non-ocular GVHD group (Figure 2a ). In addition, the incidence of chronic GVHD in the skin, gastrointestinal tract, liver, oral mucosa and lungs was significantly higher in the ocular GVHD group compared with the non-ocular GVHD group (Figure 2b) . Values are n (%) unless otherwise specified.
a Others: CLL, diffuse large B-cell lymphoma, peripheral T-cell lymphoma, natural killer/T-cell lymphoma, non-Hodgkin lymphoma, mantle cell lymphoma, acute promyeloblastic lymphoma, plasma cell myeloma, T-cell lymphoblastic leukemia, myelofibrosis, primary myelofibrosis, Fanconi's anemia, mature B-cell lymphoma, acute promyelocytic leukemia, subcutaneous panniculitus T-cell lymphoma, Ph+ mixed phenotype acute leukemia, hemophagocytic lymphohistiocytosis, biphena type, acute leukemia, angioimmunoblastic lymphoma.
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DISCUSSION
We analyzed the incidence, risk factors and severity of chronic ocular GVHD in a large, single-center cohort over 4 consecutive years. The reported incidence of ocular GVHD and DED varies between studies, ranging from 4.8 to 60%. Ivanir et al. 18 reported that, among the 111 allo-HSCT patients in their study, 28% had high Ocular Surface Disease Index scores, 31% had a very low tear break-up time, 50% had a low Schirmer test score in at least one eye (severe dry eye) and 37% had chronic ocular GVHD. Jacob et al. 10 studied 172 patients and analyzed the prevalence of risk factors associated with ocular GVHD as defined by the NIH consensus criteria. Ocular GVHD was diagnosed in 16% at 100 days and 23% at 4100 days. Our current study showed that the adjusted incidence was 1.33% for acute ocular GVHD and 33.33% for chronic ocular GVHD, which was similar to that reported in previous studies. Tabbara et al. 15 retrospectively observed 620 patients over a 10-year period and reported that chronic GVHD occurred in 5.5% of patients, DED occurred in 4.8%, corneal ulcers occurred in 2.4% and major vision-threatening ocular complications occurred in 13%. Their relatively low incidence of GVHD may be due to the retrospective chart review design, which could have underestimated the frequency of ocular GVHD and DED. However, all of these studies (including ours) may have been biased by underestimation or overestimation, owing to the ambiguous diagnostic criteria for ocular GVHD, combined with the retrospective nature of the analysis.
In one previous study, differences were observed in the severity of KCS according to the severity of the accompanying systemic GVHD. 15 Among KCS patients with systemic GVHD, 28% had grade I, 41% had grade II and 31% had grade II. Among KCS patients without systemic evidence of GVHD, 73% had grade I, 17% had grade II and 10% had grade III. However, our results are dissimilar, as we observed that ocular GVHD only occurred with systemic GVHD involvement. In addition, the severity of ocular GVHD that we observed was milder than in the previous study, with 480% of our ocular GVHD patients having grade I GVHD at the initial diagnosis, as well as after 2 years of follow-up. This discrepancy may be due to the use of different KCS and ocular GVHD grading systems in the two studies. The previous study graded KCS according to the area of superficial punctuate keratopathy, while our study graded ocular GVHD according to the NIH staging, which includes subjective symptoms and impairment of daily activities. Moreover, the NIH classification system does not allow for the diagnosis of ocular GVHD if evidence of systemic involvement is not observed.
Interestingly, Ivanir et al. 18 have reported that, although many patients were either asymptomatic or did not seek ophthalmic examination, severe dry eye was commonly observed after allo-HSCT. In another retrospective analysis of visual acuity, 98.4% of the 429 consecutive patients with chronic GVHD had visual acuity of ⩾ 20/40 in at least one eye at the initial evaluation, and 96.5% of patients retained visual acuity of ⩾ 20/40 at the last follow-up. 19 Decreased corneal sensitivity 20 and partial preservation of visual acuity may lead to ignoring changes in the ocular surface after allo-HSCT. Therefore, regular follow-up and patient education after allo-HSCT is important, even if they have no ocular discomfort and good visual acuity.
There are several risk factors that have been reported for chronic GVHD. A history of acute GVHD is known to be a strong risk factor for chronic GVHD development, [21] [22] [23] [24] and other risk 23 no use of antithymocyte globulin 27 and CML. 22, 24 Regarding risk factors for ocular GVHD, several studies have suggested that prior acute skin GVHD was an independent predictor for ocular GVHD, 10,12 and we also observed that skin involvement during the acute and chronic stages was correlated with the onset of ocular GVHD. During the acute and chronic stages, GVHD in the gastrointestinal tract and liver was also correlated with the occurrence of ocular GVHD, as was GVHD in the oral mucosa and lungs during the chronic stage. In addition, the number of chronically involved organs was correlated with the occurrence of ocular GVHD in our study. The ductal area includes the lacrimal glands, meibomian glands, salivary glands, hepatic ducts and lung ducts, while the inner surface of the ductal area is composed of a mucosal membrane, which is frequently targeted by T-cells or other inflammatory cells. [28] [29] [30] Therefore, it has been proposed that the conjunctiva may mirror systemic mucosal membranes, such as those in the intestines, lungs and oral mucosa. 29 In our study, we observed that preexisting diabetes was an independent risk factor for onset of ocular GVHD. New-onset diabetes mellitus is frequently observed after HSCT and is associated with adverse transplantation outcomes. 31 However, the prognosis is largely unknown for patients with preexisting Abbreviations: BMT = bone marrow transplantation; HSCT = hematopoietic stem cell transplantation; PBSCT = PBSC transplantation. Values are n (%) unless otherwise specified. diabetes mellitus who are undergoing HSCT. Recently, Radfat et al. 32 explored the impact of preexisting diabetes mellitus on transplantation outcomes in HSCT, and their multivariate analysis found that preexisting diabetes mellitus significantly predicted adverse outcomes and decreased overall survival. Long-term diabetes has also been shown to impair the mobilization and function of hematopoietic progenitor cells in a murine model, 33 and pretransplant diabetes mellitus is known to predict outcomes of solid organ transplantation. 34 However, the mechanism by which diabetes mellitus negatively affects ocular GVHD remains unclear, although hyperglycemia may affect platelet and granulocyte recovery, or alter the immune response, especially in ocular surface. 35 It is possible that preexisting diabetes is related to DED, because diabetes mellitus is often accompanied by DED. 36 These relationships imply that controlling blood sugar levels before HSCT would be helpful in decreasing the risk of ocular GVHD. Further, one of the novel findings in our study was that the severity of ocular GVHD was relatively static from the initial diagnosis, suggesting that earlier detection of ocular GVHD may prevent a more severe manifestation.
There are several limitations of our study. First, not all patients had a baseline ophthalmic examination before allo-HSCT. NIH defined the definition of ocular GVHD as newly developed ocular changes; however, our study relied on the patient's own information. Moreover, as decreased corneal sensitivity may ignore changes in the ocular surface, the possibility of falsenegative subjects exists in this study. The exact pathophysiology and natural course of the ocular surface in ocular GVHD is not well understood, and further prospective evaluation is warranted. Second, although the baseline characteristics of patienst were not significantly different, the results of our study might not apply to the patients who did not visit ophthalmology department.
In summary, we observed that chronic GVHD in multiple organs and preexisting diabetes mellitus were risk factors for ocular GVHD in a large cohort of allo-HSCT patients. Furthermore, we recommend regular ophthalmological examination after allo-HSCT, rather than relying on the Schirmer test or subjective symptoms that are suggested by the current NIH criteria. In addition, a baseline ocular profile of tear dynamics and ocular surface parameters should be conducted before allo-HSCT. The International Chronic Ocular GVHD Consensus group has recently proposed similar diagnostic and severity scoring criteria for ocular GVHD. 37 Further verification of our results, using a prospective study design with the standard criteria, is needed.
